Friday, March 13th, 2020

08:45-09:00 Welcome

SESSION I – Rare subsets of acute leukaemia
Chair: Gail Roboz (New York)

09:00-09:20 Case-based lecture: Mixed phenotype acute leukaemias (B/M) Charles Mullighan (Memphis)
09:20-09:25 Discussion

09:25-09:45 Case-based lecture: Interface acute leukaemias (T/M) Jonathan Bond (Dublin)
09:45-09:50 Discussion

09:50-10:10 Case-based lecture: Germline predisposition to AML Lucy Godley (Chicago)
10:10-10:15 Discussion

Brief oral communication
10:15-10:20 Dasatinib Inhibits FLT3/itd and PTPN11 Mutated Acute Myeloid Leukemia Cells Overexpressing SRC Tyrosine Kinases Nathali Kaushansky (Rehovot)
10:20-10:23 Discussion

10:23-10:45 Panel discussion

10:45-11:15 Coffee Break

SESSION II – Tracking leukaemic stem cells (LSCs)
Chair: Sylvie Freeman (Birmingham)

11:15-11:35 Case-based lecture: LSC signature Andre Schuh (Toronto)
11:35-11:40 Discussion

11:40-12:00 Case-based lecture: Flow identification and monitoring of leukaemia stem cells Jacqueline Cloos (Amsterdam)
12:00-12:05 Discussion
21/02/20

12:05-12:25  Case-based lecture:  MRD monitoring in Ph-positive ALL  Emmanuelle Clapier (Paris)
12:25-12:30  Discussion

Brief oral communication
12:30-12:35  Circulating microRNAs Behaving as Minimal Residual Disease Biomarkers in Childhood ALL  Dániel János Erdélyi (Budapest)
12:35-12:38  Discussion

12:38-13:00  Panel discussion

13:00-14:40  Lunch

13:30-14:30  SATELLITE SYMPOSIUM: T-cell engaging immuno-oncology therapy in ALL: from clinical trials to real-world evidence
Speakers: Nicolas Boissel (Paris), Christina Peters (Vienna)

This symposium is organised and funded by Amgen

SESSION III – Routine diagnosis gene expression and mutational profiling
Chair: Oliver Ottmann (Cardiff)

14:40-15:00  Case-based Lecture:  Ph-like ALL diagnosis  Sabina Chiaretti (Rome)
15:00-15:05  Discussion

15:05-15:25  Case-based lecture:  Minimal / optimal gene panel in ALL?  Josep-Maria Ribera (Barcelona)
15:25-15:30  Discussion

15:30-15:50  Case-based lecture:  Minimal / optimal gene panel in AML?  Lars Bullinger (Berlin)
15:50-15:55  Discussion

Brief oral communication
15:55-16:00  Integrated Whole Genome-Transcriptome Sequencing Compared to Conventional Diagnostic Testing in Adult B-ALL  Georgina Ryland (Melbourne)
16:00-16:03  Discussion

15:55-16:25  Panel discussion

16:25-16:55  Coffee break

16:55-17:35  DEBATE 1 – All patients with intermediate-risk AML must be transplanted
Chair: Andrew Wei (Melbourne)

Audience votes “yes” or “no”

16:55-17:10  Yes  Charles Craddock (Birmingham)
17:10-17:15  Discussion

17:15-17:30  No  Gail Roboz (New York)
17:30-17:35 Discussion
Audience votes again

17:35-18:05 INTERACTIVE CASES 1 – Mutation-based therapy off-label
Chair: Jorge Sierra (Barcelona)
17:35-17:42 Targeted therapy for Ph-like ALL Sarah Tasian (Philadelphia)
17:42-17:45 Discussion
17:45-17:52 Mutation-based therapy off-label - GO for AML salvage therapy Nicolas Boissel (Paris)
17:52-17:55 Discussion
17:55-18:02 FLT3 inhibitors post-transplantation Andreas Burchert (Marburg)
18:02-18:05 Discussion

18:05-19:05 ROUNDTABLE 1 – Should we really use new targeted inhibitors as single agents ?
Chair: Christoph Röllig (Dresden)
18:05-18:25 Next-generation FLT3 inhibitors Alexander Perl (Philadelphia)
18:25-18:45 The role of IDH1/2 Inhibitors as monotherapy Courtney DiNardo (Houston)
18:45-18:55 Discussion
18:55 Mentored Poster Walks and Welcome Get Together Stand up Buffet Dinner

Saturday, March 14th, 2020

08:00-9:00 3 Simultaneous Meet the Expert sessions

   1. CNS prophylaxis and treatment in ALL Wendy Stock (Chicago)
   2. MRD as a treatment-stratifying tool in AML Sylvie Freeman (Birmingham)
   3. Acute leukaemia and pregnancy Nicolas Boissel (Paris)

SESSION IV – Addition of a 3rd agent to frontline 7+3
Chair: Andrew Wei (Melbourne)
09:10-09:30 Case-based lecture: Midostaurin Peter Paschka (Ulm)
09:30-09:35 Discussion
09:35-09:55 Case-based lecture: Addition of gemtuzumab ozogamicin to front line 3+7 chemotherapy Juliette Lambert (Versailles)
09:55-10:00 Discussion
10:00-10:20 Case-based lecture: Nucleoside analogs Thomas Pabst (Bern)
10:20-10:25 Discussion
**Brief oral communication**

10:25-10:30  **Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML**  
Alexander Perl (Philadelphia)

10:30-10:33  **Discussion**

10:25-10:55  **Panel discussion**

10:55-11:25  **Coffee Break and Poster viewing**

11:25-12:20  **ROUNDTABLE 2 – Curative options for older AML**  
Chair: Alexander Perl (Philadelphia)

11:25-11:40  Current intensive therapy of older AML patients in 2020  
Claude Gardin (Bobigny)

11:40-11:55  Liposomal daunorubicin/cytarabine  
Jorge E. Cortes (Augusta)

11:55-12:10  Defining the role of Venetoclax in older patients with AML  
Andrew Wei (Melbourne)

12:10-12:20  **Discussion**

12:20-12:40  **INTERACTIVE CASES 2**  
Chair: Arnold Ganser (Hannover)

12:20-12:27  Management of high WBC APL  
Pau Montesinos (Valencia)

12:27-12:30  **Discussion**

12:30-12:37  APL relapse after previous arsenic therapy  
Lionel Ades (Paris)

12:37-12:40  **Discussion**

12:40-14:20  **Lunch**

13:10-14:10  **SATELLITE SYMPOSIUM:**  
AML treatment: Where are we heading?  
Chair: Andrew Wei (Melbourne)  
Speakers: Konstanze Döhner (Ulm), Gail Roboz (New York)

This symposium is organized and funded by Celgene. A Bristol-Myers Squibb company

14:20-15:00  **DEBATE 2 – Best treatment for NPM1-mutated AML in the next future?**  
Chair: Hervé Dombret (Paris)

Audience votes

14:20-14:35  **Treatment of NPM1-mutated AML:**  
Intensive Standard Treatment!  
Christoph Röllig (Dresden)

14:35-14:40  **Discussion**

14:40-14:55  **Targeted agents**  
Ali Bazarbachi (Beyrouth)

14:55-15:00  **Discussion**

Audience votes again
15:00-15:25 Coffee break and Poster Viewing

SESSION V- Allogeneic hematopoietic stem cell transplantation (HSCT)
Chair: Charles Craddock (Birmingham)

Jean-Hugues Dalle (Paris)
15:45-15:50 Discussion

15:50-16:10 Case-based lecture: Haplo-identical HSCT
Jorge Sierra (Barcelona)
16:10-16:15 Discussion

16:15-16:35 Case-based lecture: Prevention and treatment of VOD – 100 years after the “Senecio Disease”
Tiago Nava (Geneva)
16:35-16:40 Discussion

Brief oral communication
16:40-16:45 Detectable Minimal Measurable Disease By Flow Cytometry
Claudia Núñez-Torrón Stock (Madrid)
before Allogeneic Transplantation Is a Factor of Poor Outcomes in Acute Myeloid Leukemia
16:45-16:48 Discussion

16:48-17:05 Panel discussion

17:20-18:20 SATELLITE SYMPOSIUM:
AML: Bringing precision medicine and MRD into clinical strategies
Chair: Jorge Sierra (Barcelona)
Speakers: Lionel Adès (Paris), Lars Bullinger (Berlin), Jorge Sierra (Barcelona)

This symposium is organised and funded by Novartis

Sunday, March 15th, 2020

08:00-09:00 3 Simultaneous Breakfast Meet the Expert Sessions

1. Therapy-related leukaemias
   Arnold Ganser (Hannover)
2. How I treat Ph+ ALL
   Oliver Ottmann (Cardiff)
3. How I treat older ALL
   Hervé Dombret (Paris)

08:30-09:30 SATELLITE SYMPOSIUM:
Waking up to a new decade of individualized treatment for AML
Chair: Jorge Sierra (Barcelona)
Speakers: Jacqueline Cloos (The Netherlands), Pau Montesinos (Valencia), Andrew Wei (Melbourne)

This symposium is organised and funded by Astellas
SESSION VI – Immunotherapy for acute leukaemia
Chair: Wendy Stock (Chicago)

09:40-10:00 Case-based lecture:
Use of blinatumomab in ALL
Max Topp (Würzburg)
10:00-10:05 Discussion

10:05-10:25 Case-based lecture:
CAR T-cells for precursor B-cell ALL
Françoise Méchinaud (Paris)
10:25-10:30 Discussion

10:30-10:50 Case-based lecture:
Immune check-point inhibitors in acute leukaemia
Navel Daver (Houston)
10:50-10:55 Discussion

Brief oral communication
10:55-11:00 Phase 1b Multicenter, Open-Label Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Andrew Wei (Melbourne)
11:00-11:03 Discussion

11:03-11:25 Panel discussion

11:25-11:55 Coffee break

11:55-12:35 DEBATE 3 – T-ALL: where are we going now?
Chair: Nicolas Boissel (Paris)

Audience votes

11:55-12:10 Standard and new options for T-ALL
David Teachey (Philadelphia)
12:10-12:15 Discussion

12:15-12:30 Targeting T cell Malignancies with CRISPR/Cas9 Gene Edited Universal CART
John DiPersio (Saint-Louis)
12:30-12:35 Discussion

Audience votes again

12:35-12:45 Closing remarks

MEETING CLOSURE